Bayer Orion win FDA priority review for darolutamide in prostate cancer

Bayer, Orion win FDA priority review for darolutamide in prostate cancer

07:28 EDT 1 May 2019 | PharmaTimes

Darolutamide is an investigational, non-steroidal androgen receptor antagonist.

Original Article: Bayer, Orion win FDA priority review for darolutamide in prostate cancer

More From BioPortfolio on "Bayer, Orion win FDA priority review for darolutamide in prostate cancer"